Progesterone Troche (Each)

Progesterone Troches are a convenient and effective way to supplement progesterone, a naturally occurring hormone that plays a vital role in regulating menstrual cycles, supporting pregnancy, and maintaining hormonal balance. These troches are designed to dissolve slowly in the mouth, allowing for better absorption through the mucous membranes. They are often prescribed for individuals experiencing hormonal imbalances, menopausal symptoms, or progesterone deficiency. Progesterone Troches provide a targeted approach to hormone support while offering ease of use and controlled dosing.

Progesterone in the troches works by mimicking the body’s natural hormone production. It binds to progesterone receptors in various tissues, helping regulate the menstrual cycle, prepare the uterine lining for pregnancy, and maintain a healthy balance between estrogen and progesterone. By supporting these processes, the troches can alleviate symptoms like mood swings, irregular periods, and hot flashes. The sublingual absorption route bypasses the digestive system, allowing the hormone to enter the bloodstream more directly, which may enhance its effectiveness in managing symptoms related to hormonal fluctuations.

Progesterone Troches should not be used by individuals with a known allergy to progesterone or any of the inactive ingredients. They are also contraindicated in people with certain hormone-sensitive cancers, unexplained vaginal bleeding, liver disorders, or blood clotting issues unless approved by a healthcare provider. It is important to inform your doctor of any other medications, supplements, or medical conditions before starting treatment, as interactions may occur. Regular monitoring may be necessary to ensure safety and effectiveness. Do not exceed the recommended dose and store the product away from children.

Possible interactions include: barbiturate; medications for seizures or sleep; bexarotene; carbamazepine; ethotoin; ketoconazole; phenytoin; rifampin This list might not include every conceivable interaction. List every prescription, herbal, non-prescription medicine, or dietary supplement you take for your health care professional. Inform them as well whether you smoke, consume alcohol, or utilize unlawful drugs. Certain things could react with your prescriptions.

Other intravaginal medications (such as vaginal antifungals, clotrimazole, miconazole terconazole, et al.) should not be used with vaginal formulations of progesterone (e.g. Crinone, Endometrin, and Prochieve). or tioconazole) because combined usage might affect progesterone absorption and discharge from the vagina. Avoid the interplay by dividing the administration’s times. The producers of Crinone and Prochieve note that other intravaginal products can be employed as long as six hours have passed either before or after vaginal progesterone. Typically not recommended for use with other vaginal items (e.g., antifungal medicines), Endometrin can change progesterone release and absorption from the vaginal. though other vaginal products should be utilized if medically required, be informed that the response to Endometrin could be changed. Insert and the possibility for interaction have not been officially evaluated.

Most individuals tolerate Progesterone Troches well, though some may experience side effects, especially during the early stages of supplementation. Common reactions include headaches, breast tenderness, mild dizziness, and temporary bloating. Some users may notice changes in mood or sleep patterns as their hormone levels adjust. Rare but serious side effects may include severe allergic reactions, unusual weight gain, or irregular heartbeat. If any concerning symptoms persist or worsen, discontinue use and seek medical advice.

Progesterone is a critical hormone during pregnancy, and in some cases, Progesterone Troches may be prescribed to support early pregnancy under medical supervision. However, self-administering the troches without professional guidance is not recommended, as incorrect dosing can affect both the mother and the developing fetus. Breastfeeding mothers should consult their healthcare provider before using progesterone supplements, as the hormone may pass into breast milk. A careful assessment of benefits versus risks will help ensure that both mother and child remain safe while addressing hormonal needs.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond-use date. Do not flush unused medications or pour down a sink or drain

1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Eng J Med 2003;348:2379-85.
2. ACOG Committee on Obstetric Practice. Committee Opinion: use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102:1115-6.
3. Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-8.
4. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
5. Endometrin (progesterone) vaginal insert package insert. Hunt Valley, MD: Pharmaceutics International, Inc.; 2014 Jun.
6. Crinone (progesterone vaginal gel) package insert. Parsippany, NJ: Watson Pharma, Inc.; 2011 Dec.
7. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
8. Prometrium® (progesterone) package insert. Marietta, GA: Solvay Pharmaceuticals Inc.; 1998 Dec.
9. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: A randomized controlled trial (WHIMS). JAMA 2003;289:2651-62.
10. Endometrin® (progesterone) package insert. Hunt Valley, MD: Pharmaceutics International, Inc.; 2007 Jun.
11. Prochieve® (progesterone) package insert. Livingston, NJ: Columbia Laboratories, Inc.; 2004 Oct.
12. Dilantin® Kapseals® (extended phenyotin sodium capsules, USP) package insert. Morris Plains, NJ: Parke Davis; 1999 Aug.
13. Cerebyx® (fosphenytoin sodium) package insert. New York, NY: Parke-Davis; 2002 Jun.
14. Peganone® (ethotoin) package insert. Deerfield, IL: Ovation Pharmaceuticals, Inc.; 2003 Sep.
15. Tegretol® (carbamazepine) package insert. East Hanover, NJ. Novartis Pharmaceuticals; 2003 Sept.
16. Carbatrol® (carbamazepine) package insert. Wayne, PA. Shire US Inc; 2006 Jul.
17. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263—72.
18. Berman ML, Green OC. Acute stimulation of cortisol metabolism by pentobarbital in man. Anesthesiology 1971;34:365—9.
19. Phenobarbital Tablets, USP package insert. Elizabeth, NJ: Purepac Pharmaceuticals; 2000 Oct.[/fnElestrin™ (estradiol) package insert. San Antonio,TX: DPT Laboratories, Ltd.; 2006 Dec.
20. Lewis DP, VanDyke DC, Stumbo PJ, et al. Drug and environmental factors associated with adverse pregnancy outcomes Part 1: Antiepileptic drugs, contraceptives, smoking and folate. Ann Pharmacother 1998;32:802—17.
21. Hansten P, Horn J. The Top 100 Drug Interactions: A Guide to Patient Management. includes table of CYP450 and drug transporter substrates and modifiers (appendices). H & H Publications, LLP 2014 edition.
22. Kyriazopoulou V, Parparousi O, Vagenakis A. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984;59:1204—6.
23. Elestrin™ (estradiol) package insert. San Antonio,TX: DPT Laboratories, Ltd.; 2006 Dec.
24. Archer JSM, Archer DF. Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 2002;46:917—23.
25. Dickinson BD, Altman RD, Nielsen NH, Sterling ML, for the Council on Scientific Affairs, American Medical Association (AMA). Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001;98:853—60. Review.
26. Uniphyl® (theophylline, anhydrous) tablets package insert. Stamford, CT: Purdue Pharmaceutical Products LP; 2004 Mar.
27. Biaxin® (clarithromycin) package insert. North Chicago, IL: Abbott Laboratories; 2007 March.
28. Cardizem® CD (diltiazem) package insert. Kansas City, MO: Aventis Pharmaceuticals, Inc.; 2007 Sep.
29. VFEND® (voriconazole) package insert. New York,NY: Pfizer Inc; 2008 Mar.
30. Emend® capsules (aprepitant) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2007 Nov.
31. Parlodel (bromocriptine) package insert. East Hanover, NJ: Novartis Pharmaceutical Corporation, Inc.; 2003 Mar.
32. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 1993;11:2417—26.
33. Targretin® (bexarotene capsules) package insert. San Diego CA: Ligand Pharmaceuticals Inc.; 2003 April.
34. Tracleer® (bosentan) package insert. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 2007 Feb.
35. Saha GB. Fundamentals of nuclear pharmacy. 3rd ed. New York: Springer-Verlag New York, Inc.; 1992.
36. Progesterone capsule package insert. High Point, NC: Banner Pharmacaps Inc; 2013 Nov.
37. Prochieve (progesterone) vaginal gel package insert. Livingston, NJ: Columbia Laboratories, Inc.; 2009 Nov.
38. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
39. World Health Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
40. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.